Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to collect information and to evaluate the effects, good or
bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate
cancer that are undergoing radical prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Mary-Ellen Taplin, MD
Collaborators:
Beth Israel Deaconess Medical Center Duke University Genentech, Inc. Sanofi